Looks like a good deal, especially considering amount of draw down, conditions attached to the loan facility, interest chargeable and at the end mc of the company.
Most of the asx listed companies are unable to get that type of deal with very little colaterals.
I had seen deals of EOS and AVH and they were much expencier than this one and on top those companies were selling their products as well.
Hopefully this will take us past phase 3 trials. Think about the demand for a drug which can work well on bacterial resistant antibiotics.
To me it looks quite positive.
dyor
Ann: Recce Signs Debt Facility with Avenue Capital Group, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12222 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10976 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |